Literature DB >> 25671264

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Alice T Shaw, Benjamin J Solomon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25671264     DOI： 10.1056/NEJMc1415359

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

Review 2.  Oncogene-addicted non-small cell lung cancer and immunotherapy.

Authors:  Georgios Tsakonas; Simon Ekman
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Authors:  Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard
Journal:  JAMA Oncol       Date:  2016-08-01       Impact factor: 31.777

4.  Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.

Authors:  Guanggui Ding; Jian Wang; Peikun Ding; Yuxin Wen; Lin Yang
Journal:  Cancer Biol Ther       Date:  2019-02-11       Impact factor: 4.742

Review 5.  The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

Authors:  Alessia Spagnuolo; Matteo Muto; Fabio Monaco; Giuseppe Colantuoni; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 6.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

7.  Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

Authors:  Adrian G Sacher; Suzanne E Dahlberg; Jennifer Heng; Stacy Mach; Pasi A Jänne; Geoffrey R Oxnard
Journal:  JAMA Oncol       Date:  2016-03       Impact factor: 31.777

8.  Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger.

Authors:  X Pan; T Lv; F Zhang; H Fan; H Liu; Y Song
Journal:  Clin Transl Oncol       Date:  2018-02-19       Impact factor: 3.405

9.  Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

Authors:  James H Suh; Adrienne Johnson; Lee Albacker; Kai Wang; Juliann Chmielecki; Garrett Frampton; Laurie Gay; Julia A Elvin; Jo-Anne Vergilio; Siraj Ali; Vincent A Miller; Philip J Stephens; Jeffrey S Ross
Journal:  Oncologist       Date:  2016-05-05

10.  Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

Authors:  Anton Safonov; Shiyi Wang; Cary P Gross; Divyansh Agarwal; Giampaolo Bianchini; Lajos Pusztai; Christos Hatzis
Journal:  Breast Cancer Res Treat       Date:  2016-01-09       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.